Covid19
Conditions
Brief summary
Severe Acute Respiratory Syndrome-Corona Virus-2 infection results in a mild infection in most of the patients. However, 15-20% require hospitalization, and among them, 15-20% will develop acute respiratory failure, leading to their admission in Intensive Care Unit. There are no accepted predictive criteria for aggravation. Severe forms of Coronavirus induced disease-19 (COVID-19) are the consequence of endotheliopathy, and hyperinflammatory and pro-coagulant state. The Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) is an immunoreceptor that acts as an amplifier of the inflammatory response. TREM-1 is expressed on myeloid and endothelial cells. Its activation leads to endothelial activation and damage, hyperinflammatory, and pro-coagulant state. TREM-1 activation is associated with poor outcome during septic shock and myocardial infarction. We here aim at investigating the relationship between TREM-1 pathway activation and clinical degradation and outcome of COVID-19 hospitalized patients.
Interventions
OTHERblood sampling
Blood will be collected every 3 days until Day 28, discharge, or death
Sponsors
University Hospital, Limoges
Inotrem
Central Hospital, Nancy, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Consecutive COVID-19 hospitalized patients for less than 3 days
Exclusion criteria
No consent Pregnancy protected populations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prognostic value of the TREM-1 pathway activation on clinical worsening | day 28 |
Countries
France
Outcome results
None listed